Qiagen (NYSE:QGEN) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Qiagen (NYSE:QGEN) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $50.07.

QGEN has been the subject of a number of research analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $52.50 price objective (up from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Morgan Stanley reaffirmed an “equal weight” rating and set a $46.67 price objective (down from $48.61) on shares of Qiagen in a report on Monday, January 6th. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. Finally, HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $47.64 price objective for the company. in a report on Thursday, October 17th.

Institutional Trading of Qiagen

Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its position in Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after buying an additional 500 shares during the last quarter. Massmutual Trust Co. FSB ADV lifted its position in shares of Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after purchasing an additional 243 shares during the last quarter. Geneos Wealth Management Inc. lifted its position in shares of Qiagen by 41.5% during the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock worth $38,000 after purchasing an additional 251 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Qiagen during the third quarter worth $53,000. Finally, MassMutual Private Wealth & Trust FSB lifted its position in shares of Qiagen by 83.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,565 shares of the company’s stock worth $70,000 after purchasing an additional 712 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors.

Qiagen Trading Up 0.3 %

Qiagen stock opened at $44.66 on Monday. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. Qiagen has a 12-month low of $40.15 and a 12-month high of $49.30. The firm has a 50 day moving average of $43.72 and a 200 day moving average of $43.21. The firm has a market capitalization of $9.91 billion, a price-to-earnings ratio of 111.32, a P/E/G ratio of 3.03 and a beta of 0.37.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.